|
Have
you ever wondered how new drugs are researched? The
following item gives some insight into the process.
Nuevolution
Generates World's Largest Drug Library And Identifies Novel High Potency
Cancer Leads
COPENHAGEN
,
Denmark
, April 19/PRNewswire/ --
Nuevolution A/S, a privately held drug discovery company
announced
that
it has generated what it believes to be the world's largest drug-like
library
comprising 100 million diverse compounds synthesised in a single test
tube.
The Company also identified novel drug lead candidates that inhibit the
cancer
target, integrin avBeta3 directly from this unprecedented library.
Both
library generation and lead candidate identification were performed in
days
using Nuevolution's proprietary Chemetics (r) drug discovery technology.
"The generation of this unique "ultra-large" compound
library and the
subsequent
rapid identification of novel high potency drug candidates clearly
demonstrate
the tremendous power of Chemetics (r) and represent a major
milestone
to establishing Nuevolution as a leading drug discovery Company",
commented
Zahed Subhan PhD, Chief Executive Officer of Nuevolution A/S.
Chemetics
(r) is poised to truly revolutionize the drug discovery process -
it
is the only technology available today that successfully combines
ultra-large
libraries of billions to trillions of drug-like small molecules
with
an accurate selection method that can efficiently handle such enormous
numbers
of compounds".
"We are looking forward to building on these impressive
achievements by
consolidating
our internal drug discovery pipeline as well as forging drug
discovery
alliances with leading pharmaceutical and biotech companies", added
Dr
Subhan.
About Nuevolution A/S
Nuevolution
is a unique drug discovery company poised to revolutionize
drug
discovery and development by utilizing its proprietary Chemetics (r)
technology
to rapidly generate tens to hundreds of potent, structurally
diverse,
small molecule clinical candidates to virtually any target in a
matter
of weeks.
Chemetics
(r) represents the ultimate "convergent" drug discovery
technology
- it is a unique, patent protected hybrid of proven wet chemistry
and
molecular biology approaches that enables the rapid synthesis and
accurate
selection of billions to trillions of chemically diverse, drug-like
compounds
in a single test tube. Chemetics (r) allows Nuevolution to generate
unprecedented
numbers of potent and (target sub-type) selective drug leads in
weeks,
thus addressing the major current bottleneck in drug discovery and
development.
By applying it's Chemetics (r) technology to recognised disease targets,
Nuevolution
has identified novel, drug-like, small molecules with the
potential
to address major unmet medical needs.
Nuevolution also seeks to leverage its broadly applicable Chemetics (r)
drug
discovery engine through drug discovery partnerships with leading
pharmaceutical
and biotechnology companies.
Nuevolution A/S currently employs 31 world class scientists and business
professionals,
including 18 Ph.D. qualified individuals. The company was
founded
in May 2001 and is currently headquartered in
Copenhagen
,
Denmark
.
To date, Nuevolution has raised $ 24 million in venture capital based on
the
ongoing development of its proprietary Chemetics (r) technology.
Investors
include Novo A/S, Nordic Biotech K/S, The Danish Investment Fund,
SEB
Företagsinvest and Scandinavian Life Science Venture. Nuevolution
recently
(October 2003) closed the first round of a Series B financing
amounting
to $ 15 million.
www.nuevolution.com
(26/4/04)
|
